Recent Reports


Evidence report on sickle cell disease. This report will serve as the basis for discussion during a public meeting of the New England CEPAC on March 26, 2020.

View More on this Topic

An at-a-glance summary of ICER’s full report.

View More on this Topic

ICER’s final report on acute migraine treatments, including a summary of the public meeting and key policy recommendations.  

View More on this Topic

ICER’s Draft Evidence Report on treatments for cystic fibrosis, open to public comment until March 18th. For more information on submitting a public comment, please visit ourstakeholder engagement page. 

View More on this Topic

Materials

New England CEPAC

Hemophilia A: Evidence Presentation

New England CEPAC

Supervised Injection Facilities: Open Input

Midwest CEPAC

Bladder Cancer: Open Input

Midwest CEPAC

Digital Apps for OUD: Open Input

Midwest CEPAC

Bladder Cancer: Stakeholder List

Midwest CEPAC

Bladder Cancer: Draft Scoping Document

Midwest CEPAC

Digital Apps for OUD: Stakeholder List

Midwest CEPAC

Digital Apps for OUD: Draft Scoping Document

Midwest CEPAC

Acute Migraine: Policy Recommendations

ICER

2020 Value Assessment Framework: Response to Comments

CTAF

RA Update: Final Policy Recommendations

ICER

2020 Value Assessment Framework: Final Webcast to Explain Updates